MErCuRIC1: a phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients [abstract]
Frequently Asked Questions About Peptides and FDA Regulation Has the FDA removed peptides from Category 2
All three individual compounds are also available as standalone products in our catalog, where their evidence bases are summarized in greater depth
Youll find advocates in both camps, but our experience, backed by biochemical principles, points strongly in one direction
One reconstitutes the toxin and the patient barely flinches
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited